438 related articles for article (PubMed ID: 21306997)
1. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
Sunaga N; Imai H; Shimizu K; Shames DS; Kakegawa S; Girard L; Sato M; Kaira K; Ishizuka T; Gazdar AF; Minna JD; Mori M
Int J Cancer; 2012 Apr; 130(8):1733-44. PubMed ID: 21544811
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
[TBL] [Abstract][Full Text] [Related]
5. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
Moran DM; Trusk PB; Pry K; Paz K; Sidransky D; Bacus SS
Mol Cancer Ther; 2014 Jun; 13(6):1611-24. PubMed ID: 24688052
[TBL] [Abstract][Full Text] [Related]
8. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
[TBL] [Abstract][Full Text] [Related]
9. Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.
Mao CQ; Xiong MH; Liu Y; Shen S; Du XJ; Yang XZ; Dou S; Zhang PZ; Wang J
Mol Ther; 2014 May; 22(5):964-73. PubMed ID: 24496383
[TBL] [Abstract][Full Text] [Related]
10. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
Gandhi J; Zhang J; Xie Y; Soh J; Shigematsu H; Zhang W; Yamamoto H; Peyton M; Girard L; Lockwood WW; Lam WL; Varella-Garcia M; Minna JD; Gazdar AF
PLoS One; 2009; 4(2):e4576. PubMed ID: 19238210
[TBL] [Abstract][Full Text] [Related]
11. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
[TBL] [Abstract][Full Text] [Related]
12. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.
Wang M; Kern AM; Hülskötter M; Greninger P; Singh A; Pan Y; Chowdhury D; Krause M; Baumann M; Benes CH; Efstathiou JA; Settleman J; Willers H
Cancer Res; 2014 May; 74(10):2825-34. PubMed ID: 24648348
[TBL] [Abstract][Full Text] [Related]
13. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.
Zhang XC; Zhang J; Li M; Huang XS; Yang XN; Zhong WZ; Xie L; Zhang L; Zhou M; Gavine P; Su X; Zheng L; Zhu G; Zhan P; Ji Q; Wu YL
J Transl Med; 2013 Jul; 11():168. PubMed ID: 23842453
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
Jiang Y; Yuan Q; Fang Q
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1087-95. PubMed ID: 24728492
[TBL] [Abstract][Full Text] [Related]
16. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
17. Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.
Lee WY; Chen PC; Wu WS; Wu HC; Lan CH; Huang YH; Cheng CH; Chen KC; Lin CW
Int J Cancer; 2017 Nov; 141(9):1921-1931. PubMed ID: 28710768
[TBL] [Abstract][Full Text] [Related]
18. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
19. The genetics and biology of KRAS in lung cancer.
Westcott PM; To MD
Chin J Cancer; 2013 Feb; 32(2):63-70. PubMed ID: 22776234
[TBL] [Abstract][Full Text] [Related]
20. ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.
Luk PP; Galettis P; Links M
Lung Cancer; 2011 Sep; 73(3):274-82. PubMed ID: 21277645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]